Zydus Lifesciences’ wholly owned subsidiary -- Sentynl Therapeutics Inc., USA, (Sentynl) has acquired worldwide proprietary rights to Zokinvy (lonafarnib) from Eiger Biopharmaceuticals Inc., USA (Seller), pursuant to an asset purchase agreement (APA), adding to portfolio of biopharmaceuticals for rare and ultra-rare diseases.
Zokinvy is approved in the U.S. (2020), European Union and Great Britain (2022), and Japan (2024) for the treatment of Progeria, a collection of ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1515.00 |
Dr. Reddys Lab | 6080.25 |
Cipla | 1565.50 |
Zydus Lifesciences | 1110.95 |
Lupin | 1601.00 |
View more.. |